NCT05712486

Brief Summary

Athletic osteitis pubis is a high prevalent pathology among athletes, especially in those who make quick change of direction of the movement, like runners or footballers. Despite the fact that there is evidence about conservative treatments, there is a lack of evidence about manual therapy (MT) techniques applied in isolation and its consequences in pain and range of movement. The investigators decided to conduct a randomized controlled trial to compare the effects of a MT technique with placebo technique.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
36

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Feb 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 16, 2023

Completed
16 days until next milestone

Study Start

First participant enrolled

February 1, 2023

Completed
2 days until next milestone

First Posted

Study publicly available on registry

February 3, 2023

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 30, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 30, 2025

Completed
Last Updated

March 25, 2026

Status Verified

October 1, 2025

Enrollment Period

2.7 years

First QC Date

January 16, 2023

Last Update Submit

March 20, 2026

Conditions

Outcome Measures

Primary Outcomes (4)

  • Actual PAIN

    actual pain reported by the patient using visual analog scale (VAS) from 0 to 10, in which higher scores are worse.

    Baseline

  • Actual PAIN

    actual pain reported by the patient using visual analog scale (VAS)from 0 to 10, in which higher scores are worse.

    after to two weeks of treatment

  • Last week PAIN

    past week pain reported by the patient using visual analog scale (VAS) from 0 to 10, in which higher scores are worse.

    Baseline

  • Last week PAIN

    past week pain reported by the patient using visual analog scale (VAS) from 0 to 10, in which higher scores are worse.

    after to two weeks of treatment

Secondary Outcomes (13)

  • Range of Movement (ROM)

    Baseline

  • Range of Movement (ROM)

    after to two weeks of treatment

  • Pain in sport activities

    Baseline

  • Pain in sport activities

    After two weeks of treatment

  • Pain intensity in pain provocation tests: Single adductor, squeeze and bilateral adductor tests

    Baseline

  • +8 more secondary outcomes

Study Arms (2)

Lateral distraction group

EXPERIMENTAL

High force lateral distraction of affected hip.

Other: High force hip Lateral distraction

Placebo distraction group

SHAM COMPARATOR

Placebo lateral traction of affected hip.

Other: Placebo force hip lateral distraction

Interventions

Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying high force of distraction.

Lateral distraction group

Hip lateral distraction in adjusted position of maximun flexion and internal rotation, with neutral position of abduction/adduction applying placebo force of distraction.

Placebo distraction group

Eligibility Criteria

Age18 Years - 40 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Athletes diagnosed with osteitis pubis stage 1 with at least 3 months of evolution.
  • Internal rotation ROM limited.
  • Positive provocation pain tests.

You may not qualify if:

  • Pain due to intraarticular hip pathology.
  • Hip pain due to inflamatory diseases.
  • Previous surgical interventions in hip, pelvis or lumbar spine.
  • MRI results or provocation pain tests inconcluyent.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Silvia Lahuerta Martín

Soria, Spain

Location

Study Officials

  • Silvia Lahuerta Martín

    University of Valladolid

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Masking Details
Double- blind
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PH D student

Study Record Dates

First Submitted

January 16, 2023

First Posted

February 3, 2023

Study Start

February 1, 2023

Primary Completion

October 30, 2025

Study Completion

October 30, 2025

Last Updated

March 25, 2026

Record last verified: 2025-10

Data Sharing

IPD Sharing
Will not share

Locations